TickerGuard
Buy Day today: Good (63) Broad market participation · no major macro event
DNA

Ginkgo Bioworks Holdings

Healthcare · Biotechnology

7.40$ +6.3% vs. previous close Closing price · As of: Aug 21, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Ginkgo Bioworks Holdings (DNA). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — DNA
Segment 2021 2022 2023
Cell Engineering $113.0M 36.0% $143.7M 30.1% · +27.2% $143.5M 57.1% · -0.1%
Biosecurity $200.8M 64.0% $334.0M 69.9% · +66.3% $107.9M 42.9% · -67.7%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Operating income — DNA
Segment 2021 2022 2023
Cell Engineering -$122.1M -108.0% -$298.3M -207.6% -$425.2M -296.3%
Biosecurity $9.1M 4.5% $71.5M 21.4% -$3.2M -3.0%

Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.

Revenue by product line

Revenue by product line — DNA
Segment 2021 2022 2023 2024 2025
Cell Engineering revenue $113.0M 36.0% $143.7M 30.1% · +27.2% $143.5M 57.1% · -0.1% $174.0M 76.6% · +21.2% $132.7M 78.0% · -23.7%
Service $177.8M 56.7% $298.6M 62.5% · +67.9% $79.0M 31.4% · -73.6% $53.1M 23.4% · -32.8% $37.4M 22.0% · -29.5%
Product $23.0M 7.3% $35.5M 7.4% · +53.9% $28.9M 11.5% · -18.4% $0 0.0% · -100.0% $0 0.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?